Vaxcyte: Funding, Investors & Team (Sep 2026)
Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).
Vaxcyte has raised $2.2B across 4 funding rounds on record, the most recent an undisclosed round of $1.5B announced in Sep 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Vaxcyte Company Profile and Key Stats
Latest funding round on record: Sep 2024.
Vaxcyte Funding Rounds
Vaxcyte raised $3.2M in a Grant announced in Aug 2021.
5 months later, a Post-IPO Equity of $100M was announced in Jan 2022.
9 months later, a Post-IPO Equity of $600M was announced in Oct 2022.
1.9 years later, an undisclosed round of $1.5B was announced in Sep 2024.
Vaxcyte Founders and Leadership Team
Contact details for the Vaxcyte team: 2 of 2 have an email address on file.
Start 14-day free trial →Vaxcyte Funding Compared to Other Biotechnology Startups
Vaxcyte's latest round of $1.5B is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Vaxcyte in Biotechnology and Foster City
Companies Similar to Vaxcyte
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Vaxcyte Funding FAQs
What does Vaxcyte do?
Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).
How much funding has Vaxcyte raised?
Vaxcyte has raised $2.2B across 4 rounds on record. The most recent is an undisclosed round of $1.5B announced in Sep 2024.
When did Vaxcyte last raise funding?
Vaxcyte's most recent funding round on record is an undisclosed round of $1.5B, announced in Sep 2024.
Who founded Vaxcyte?
FundedIQ lists Grant E Pickering (Founder) at Vaxcyte.
Who is the CEO of Vaxcyte?
Grant Pickering is listed as CEO at Vaxcyte.
Where is Vaxcyte headquartered?
Vaxcyte is based in Foster City, California, United States.
How many employees does Vaxcyte have?
Vaxcyte is in the 51-100 employee band.
How does Vaxcyte's funding compare to other Biotechnology startups?
Vaxcyte's latest round of $1.5B is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Vaxcyte Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Vaxcyte is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.